Iclusig (Ponatinib)

Iclusig is indicated for hematologic malignancies driven by the BCR‑ABL tyrosine kinase pathway.

• Chronic myeloid leukemia (CML) resistant or intolerant to prior therapy: provides disease control when earlier treatments have failed.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): offers targeted therapy for patients with this specific genetic abnormality.

• Ponatinib binds to the ATP‑binding pocket of the BCR‑ABL tyrosine kinase, including the T315I mutant, thereby blocking phosphorylation of downstream signaling proteins. This inhibition halts proliferation and survival signals in leukemic cells. The drug also suppresses other kinases such as VEGFR, FGFR and PDGFR, contributing to its broader antitumor activity in resistant disease.

Ponatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hypertension: elevated blood pressure often requiring medical management.
• Rash: skin eruptions that may be mild to moderate.
• Nausea: gastrointestinal discomfort occurring early in treatment.
• Fatigue: persistent tiredness affecting daily activities.

Serious or Rare Side Effects

• Arterial occlusive events: including myocardial infarction and stroke.
• Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism.
• Hepatotoxicity: significant liver enzyme elevations or liver injury.

When prescribing Ponatinib, clinicians should observe several safety measures to minimize risk.

• Monitor blood pressure: check regularly and treat hypertension promptly.
• Assess liver function: perform baseline and periodic liver enzyme tests.
• Evaluate cardiovascular status: screen for arterial disease before and during therapy.
• Avoid strong CYP3A4 inhibitors: these can increase ponatinib exposure and toxicity.
• Pregnancy and lactation: drug is contraindicated in pregnancy; advise effective contraception and avoid breastfeeding.
• Store at room temperature: keep tablets in the original container, protect from moisture and light.

Ponatinib interacts with several medicines; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ponatinib plasma levels and increase toxicity.
• Antiplatelet agents combined with anticoagulants: heighten risk of severe bleeding.
• Other tyrosine kinase inhibitors: concurrent use can amplify overlapping toxicities.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower ponatinib concentrations, reducing efficacy.
• Statins metabolized by CYP3A4 (e.g., simvastatin): may require dose adjustment to avoid increased statin exposure.
• Antihypertensive drugs: blood pressure changes may need closer monitoring.